CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced a collaboration with Array BioPharma (NASDAQ: ARRY - News). Foundation Medicine will use its genomic sequencing and analytic capabilities to assess potentially relevant molecular alterations to assist Array in targeting patients that are most likely to respond to treatment.

Foundation Medicine has established a remarkable portfolio of collaborations around the discovery and clinical development of targeted cancer therapeutics, said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. The molecular information generated by our platform is designed to help biopharma companies like Array expedite the development of targeted drug candidates that impact the genomic pathways driving a specific cancer.

Array has a portfolio of targeted cancer agents in early stages of clinical development. Through this collaboration with Foundation Medicine, Array intends to determine the genetic profile of tumors of patients who are treated with certain of its anticancer agents. The goal of this work is to understand how to identify patients who may respond to a given targeted therapy to ensure that each patient gets the optimal drug to treat their individual disease.

Foundation Medicines industry and academic partnerships complement the companys core cancer diagnostics capability, a comprehensive cancer genomic test that provides physicians with genomic information that may help match patients with treatments or clinical trials specific for the genomic profile of their tumor.

About Foundation Medicines Comprehensive Cancer Genomic Test

Foundation Medicines comprehensive cancer genomic test uses next-generation sequencing to analyze routine clinical specimens (i.e., small amounts of formalin fixed, paraffin embedded tumor tissue) for molecular alterations in approximately 200 cancer-related genes. The test is optimized for clinical-grade analysis of tumor tissues, overcoming multiple complexities (such as purity, ploidy, and clonality) inherent to tumor genomes. Test results are reported through a secure, interactive website linking genomic data to a structured knowledge base of relevant, publicly available scientific and medical information. The company also aims to provide information on relevant clinical trials to enable a more rapid recruitment of patients into trials for targeted therapies. Foundation Medicines test can serve as a helpful decision-support tool for physicians to recommend cancer treatment approaches tailored to each patients molecular subtype.

About Foundation Medicine

Foundation Medicine is dedicated to improving cancer care through the development of comprehensive cancer diagnostics that will help physicians inform treatment decisions based on an individual patients molecular cancer subtype. Foundation Medicines first laboratory developed test, based on a next-generation sequencing platform, is designed to accommodate a broad landscape of cancer genome information and a growing repertoire of targeted treatments and clinical research opportunities. Foundation Medicines test will assist physicians to make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patients unique cancer-associated alterations alongside publicly available scientific and medical information. The companys founding advisors are world leaders in genome technology, cancer biology and medical oncology; they, alongside clinicians, biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the companys website at http://www.foundationmedicine.com.

See the original post:
Foundation Medicine Announces Collaboration with Array BioPharma

Comments are closed.